title: Pars plana vitrectomy for intraocular inflammation-related cystoid macular edema unresponsive to corticosteroids. A preliminary study.
abstract: OBJECTIVE
  To determine the role of pars plana vitrectomy in patients with intraocular inflammation-related cystoid macular edema that is unresponsive to corticosteroids.
  
  
  METHODS
  Eleven eyes of nine patients underwent a standard three-port pars plana vitrectomy. The primary indication was intraocular inflammation-related cystoid macular edema that was unresponsive to oral, sub-Tenon's, and topical corticosteroids. Preoperative follow-up ranged from 20 months to 144 months (average, 70 months). Postoperative follow-up ranged from 3 months to 108 months (average, 21 months).
  
  
  RESULTS
  Seven eyes (64%) improved 4 or more lines of Snellen visual acuity within 4 weeks. Two eyes (18%) remained unchanged and 2 eyes (18%) worsened. Cystoid macular edema improved by clinical examination and fluorescein angiography in 9 eyes (82%) and by clinical examination alone in 2 eyes (18%). No intraoperative complications were noted. Postoperative complications consisted of cataract formation in 1 eye (9%), glaucoma in 2 eyes (18%), and epiretinal membrane formation in 1 eye (9%).
  
  
  CONCLUSIONS
  Pars plana vitrectomy may have a role in the treatment of intraocular inflammation-related cystoid macular edema that fails to respond to corticosteroids. The subgroup of patients who benefit most remains to be identified.
authors.affiliation: Doheny Eye Institute, Los Angeles 90033.
authors.forename: P U
authors.initials: PU
authors.lastname: Dugel
authors.forename: N A
authors.initials: NA
authors.lastname: Rao
authors.forename: S
authors.initials: S
authors.lastname: Ozler
authors.forename: P E
authors.initials: PE
authors.lastname: Liggett
authors.forename: R E
authors.initials: RE
authors.lastname: Smith
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D009877:Endophthalmitis / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009915:Orbit / Q000601:surgery; D011183:Postoperative Complications; D014792:Visual Acuity; D014821:Vitrectomy
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids